![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Merck Nabs FDA Approval for Zepatier to Treat HCV Genotypes 1 and 4
Merck Nabs FDA Approval for Zepatier to Treat HCV Genotypes 1 and 4
![Merck_logo.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/Merck_logo.jpg?t=1576126512&width=430)
The FDA has blessed Merck’s Zepatier, a combination of elbasvir and grazoprevir, with or without ribavirin, for the treatment of chronic hepatitis C virus genotypes 1 and 4.
An oral treatment, Zepatier was evaluated in 1,373 patients with chronic HCV genotype 1 or 4 infections with and without cirrhosis for 12 or 16 weeks.
Zepatier was granted breakthrough therapy designation for the HCV genotype 1 infection in patients with end-stage renal disease and for chronic HCV genotype 4 infection.
Upcoming Events
-
21Oct